Long Sheng Chang

Contact Information

Call us at: (614)722-2700

Center for Childhood CancerAbigail Wexner Research Institute700 Children’s DriveColumbus, Ohio 43205 (map)

Learn more about Long-Sheng Chang

Biography

Long-Sheng Chang, PhD, is a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a professor in the Department of Pediatrics at The Ohio State University College of Medicine. Dr. Chang received his bachelor’s degree from National Taiwan University and his PhD degree from Rutgers University-New Jersey Medical School. Subsequently, he did a postdoctoral training at Princeton University. In June 1990, Dr. Chang joined the faculty at The Research Institute at Nationwide Children’s Hospital and The Ohio State University (OSU) College of Medicine. Currently he is a principal investigator in the Center for Childhood Cancer and a Professor in the OSU Department of Pediatrics. Also, he has adjunct appointment to the Departments of Biological Chemistry & Pharmacology, Otolaryngology, Pathology, and Veterinary Bioscience, Molecular Cellular & Developmental Biology (MCDB) Program, Ohio State Biochemistry Program (OSBP), and Biomedical Sciences Graduate Program (BSGP).

Academic and Clinical Areas

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Research

Lab(s)

Center for Childhood Cancer

Dr. Chang is interested in genetic diseases that predispose individuals to the development of multiple nervous system tumors and other debilitating manifestations. Over the past two decades, he has been studying neurofibromatosis (NF), particularly neurofibromatosis type 2 (NF2), which is caused by mutations in the NF2 tumor suppressor gene. Using transgenic and gene knockout approaches, his lab has discovered specific regulation of NF2 gene expression and identified novel NF2 function during neural and mammary gland development and tumorigenesis. In addition, the lab has generated several cell culture and animal models for NF2-associated schwannomas and meningiomas. Using these models, his lab has evaluated novel targeted small-molecule drugs and natural compounds and identified AR-42, a histone deacetylase inhibitor, as a potential treatment for NF2-associated tumors. In addition, Dr. Chang is interested in studying the tumors associated with other NF, including NF1 and schwannomatosis. The ultimate goal of his research is to develop efficacious medical treatments for these NF-associated nervous system tumors, ultimately leading to substantial improvement of clinical care and long-term treatment outcomes for these patients. In addition, Dr. Chang’s laboratory is investigating molecular pathogenetics of hereditary Ménière’s disease and other hearing disorders. Publications

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Professional Experience

2015 - Present Journal of Otolaryngology Head & Neck Surgery, Herald Scholarly Open Access, Editorial Board Member2014 - Present Austin Otolaryngology, Austin Publications, LLC, Editorial Board Member2013 - Present International Journal of Medicine, Science Publishing Corp., Editorial Board Member2012 - Present Journal of Applied Medical Sciences, International Scientific Press, Editorial Board Member2010 - Present International Journal of Clinical Medicine, Scientific Research Publishing, Inc., Editorial Board Member2007 - Present Department of Pediatrics, The Ohio State University College of Medicine, and Center for Childhood Cancer, Children’s Research Institute, Children’s Hospital, Professor2007 - Present Departments of Molecular Cellular Biochemistry, Pathology, Otolaryngology, and Vet. Biosci., The Ohio State University, Adjunct Professor2007 - Present Departments of Molecular Cellular Biochemistry, Pathology, Otolaryngology, and Vet. Biosci., Adjunct Professor2001 - Present Department of Otolaryngology, The Ohio State University College of Medicine, Otolaryngology Fellow Training Program Committee2001 - Present The Annual Otolaryngology Alumni Symposium, Department of Otolaryngology, The Ohio State University College of Medicine, Judge, Otolaryngology Resident, and Fellow Presentations1996 - Present Children’s Hospital Research Foundation, Children’s Hospital (Columbus, OH), Institutional Animal Care and Use Committee1993 - Present Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Oncology Training Grant Committee1990 - Present Molecular, Cellular, and Developmental Biology (MCDB) Program and Ohio State Biochemistry Program (OSBP), The Ohio State University, Member2015 - 2015 Florida Department of Health’s Bankhead-Coley Cancer Research Program Proposal Review, Reviewer2015 - 2015 Oak Ridge Institute for Science and Education (ORISE), Reviewer2015 - 2015 Oak Ridge Associated Universities (ORAU), Reviewer2015 - 2015 Committee of Initial Inquiry, Office of Research Compliance, The Ohio State University, Member2013 - 2015 Internal Advisory Committee, Brain Tumors SPORE (Specialized Program of Research Excellence), Ohio Brain Tumor Working Group, Member2013 - 2015 University Senate Committee on Academic Freedom and Responsibility, The Ohio State University, Chair2012 - 2015 The University Senate’s Committee on Academic Freedom and Responsibility, The Ohio State University, Member2014 - 2014 University Senate’s Ad Hoc Committee on New Media in the Classroom, The Ohio State University, Chair2013 - 2013 The SEI Ad Hoc Committee, The Executive Committee of Faculty Council, The Ohio State University, Member2012 - 2013 Pennsylvania Department of Health Final Performance Review - 12-13 Cycle B, Oak Ridge Associated Universities, Reviewer2012 - 2013 Welcome Trust, Peer-Review Grant Reviewer2012 - 2012 Peer-Review Grant Reviewer, The Brain Tumor Charity2006 - 2012 University Senate’s Committee on Academic Misconduct, The Ohio State University, Member2006 - 2012 University Senate’s Committee on Academic Misconduct, The Ohio State University, Member2009 - 2009 Samantha Dickson Brain Tumour Trust, Peer-Review Grant Reviewer2009 - 2009 The Department of Defense Neurofibromatosis Research Program, NF-B Review Panel, Peer-Review Scientific Reviewer2008 - 2009 The Department of Defense Neurofibromatosis Research Program, Adhoc-1 Review Panel, Reviewer2008 - 2008 Grants Committee, Medical Research Council, Referee2007 - 2007 The Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury (PTSD/TBI) Research Program Panel 2, Peer-Review Online Reviewer2007 - 2007 The Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury (PTSD/TBI) Research Program Panel 4, Peer-Review Scientific Reviewer2003 - 2007 Department of Veterinary Biosciences, The Ohio State University, Adjunct Associate Professor2001 - 2007 Department of Otolaryngology, The Ohio State University College of Medicine, Adjunct Associate Professor1998 - 2007 Department of Pathology, The Ohio State University College of Medicine, Adjunct Associate Professor1996 - 2007 Department of Molecular Cellular Biochemistry (former Medical Biochemistry), The Ohio State University College of Medicine, Adjunct Associate Professor1996 - 2007 Department of Pediatrics, Children’s Hospital and The Ohio State University, Associate Professor2006 - 2006 Grants Committee, Medical Research Council, UK, Referee1993 - 2006 Molecular Cellular Development Biology Program, The Ohio State University, Graduate Studies Committee2005 - 2005 Cancer Research Program, The US Army Medical Research and Material Command (USAMRMC) Congressionally Directed Medical Research Program (CDMRP), Peer-Review Panel Member2005 - 2005 Cancer Research Program, The US Army Medical Research and Material Command (USAMRMC) Congressionally Directed Medical Research Program (CDMRP), Peer-Review Panel Member2005 - 2005 Project Grants Committee, Cancer Research UK, Referee2002 - 2003 The Center for Childhood Cancer Bi-monthly Research Meeting, Children’s Research Institute (Columbus, OH), Organizer1998 - 2003 Ohio State Biochemistry Program, The Ohio State University, Graduate Admission Committee1999 - 1999 11th Annual Stone Lab Meeting, The Ohio State University Comprehensive Cancer Center Molecular Biology Human Cancer Genetics Program, F.T. Stone Laboratory, The Ohio State University, Organizer1998 - 1998 10th Annual Stone Lab Meeting, The Ohio State University Comprehensive Cancer Center Molecular Biology & Human Cancer Genetics Program, F.T. Stone Laboratory, The Ohio State University, Co-organizer1997 - 1998 Molecular, Cellular, & Developmental Biology Program, The Ohio State University, Rotation Research Advisory Committee1995 - 1996 Children’s Hospital (Columbus, OH), Design Task Force for Wexner Institute for Pediatric Research1995 - 1996 The Ohio State University Comprehensive Cancer Center Transgenic Mouse Facility at Children’s Hospital, The Ohio State University, Laboratory Director1993 - 1996 Biotechnology Center, The Ohio State University, Transgenic Advisory Committee1991 - 1996 Children’s Hospital Research Foundation, Children’s Hospital (Columbus, OH), Program Committee1991 - 1996 Department of Medical Biochemistry, The Ohio State University College of Medicine, Adjunct Assistant Professor1990 - 1996 Department of Pediatrics, Children’s Hospital and The Ohio State University College of Medicine (Columbus, OH), Assistant Professor1994 - 1995 Children’s Hospital Research Foundation, Children’s Hospital (Columbus, OH), Product Standardization Committee1994 - 1995 College of Medicine, The Ohio State University, Gene Therapy Task Force1992 - 1995 Children’s Hospital Research Foundation, Children’s Hospital (Columbus, OH), Strategic Planning Task Force Committee1992 - 1995 Children’s Hospital Research Foundation, Children’s Hospital (Columbus, OH), Operation Committee1991 - 1995 The Ohio State University/Children’s Hospital Transgenic Mouse Facility (Columbus, OH), Laboratory Director1988 - 1990 Department of Molecular Biology, Princeton University, Research Staff Member1985 - 1987 Leukemia Society of America, Leukemia Society Research Fellow1985 - 1985 Department of Molecular Biology, Princeton University, Research Associate

Contact Information

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Contact Information

Call us at: (614)722-2700

Center for Childhood CancerAbigail Wexner Research Institute700 Children’s DriveColumbus, Ohio 43205 (map)

Learn more about Long-Sheng Chang

Biography

Academic and Clinical Areas

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Research

Lab(s)

Center for Childhood Cancer

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Professional Experience

Contact Information

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Contact Information

Call us at: (614)722-2700

Center for Childhood CancerAbigail Wexner Research Institute700 Children’s DriveColumbus, Ohio 43205 (map)

Learn more about Long-Sheng Chang

Contact Information

Call us at:
(614)722-2700
Center for Childhood CancerAbigail Wexner Research Institute700 Children’s DriveColumbus, Ohio 43205 (map)

Learn more about Long-Sheng Chang

Biography

Dr. Chang received his bachelor’s degree from National Taiwan University and his PhD degree from Rutgers University-New Jersey Medical School. Subsequently, he did a postdoctoral training at Princeton University. In June 1990, Dr. Chang joined the faculty at The Research Institute at Nationwide Children’s Hospital and The Ohio State University (OSU) College of Medicine. Currently he is a principal investigator in the Center for Childhood Cancer and a Professor in the OSU Department of Pediatrics. Also, he has adjunct appointment to the Departments of Biological Chemistry & Pharmacology, Otolaryngology, Pathology, and Veterinary Bioscience, Molecular Cellular & Developmental Biology (MCDB) Program, Ohio State Biochemistry Program (OSBP), and Biomedical Sciences Graduate Program (BSGP).

Academic and Clinical Areas

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Hematology/Oncology & BMT

Principal Investigator

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Center for Childhood Cancer

Hematology/Oncology & BMT
Principal Investigator
Center for Childhood Cancer
Principal Investigator
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Center for Childhood Cancer

Research

Lab(s)

Center for Childhood Cancer

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Lab(s)

Center for Childhood Cancer

                  Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.

                


                  Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.

                


                  Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.

                


                  Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.

                


                  Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.

                


                  Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.

                


                  Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.

                


                  Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.

                


                  Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Lab(s)

Center for Childhood Cancer

Lab(s)

Center for Childhood Cancer

                Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.



                Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.



                Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.



                Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.



                Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.



                Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.



                Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.



                Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.



                Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

View More Publications

Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, Liu X, Belcher KA, Luo Z, Ogurek S, Reilly C, Zhou X, Zhang L, Rubin J, Chang LS, Xin M, Yu J, Suva M, Pratilas CA, Potter S, Lu QR. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022 Nov 4; 8: eabo5442.
Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6: 1008-1019.
Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021 Oct; 87: 937-948.
Amaravathi A, Oblinger JL, Welling DB, Kinghorn AD, Chang LS. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11: 698192.
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW, Synodos for NF2 Consortium.. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16: e0252048.
Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18; 21: 486-497.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium .. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 Aug 2; 20: 1185-1196.
Synodos for NF2 Consortium., Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13: e0197350.
Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 Jan; 299: 299-307.

Professional Experience

2015 - Present Journal of Otolaryngology Head & Neck Surgery, Herald Scholarly Open Access, Editorial Board Member

Contact Information

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Center for Childhood Cancer

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Call us at: (614)722-2700

                    Abigail Wexner Research Institute700 Children's DriveColumbus, Ohio 43205 (map)

Call us at:
(614)722-2700
Abigail Wexner Research Institute700 Children’s DriveColumbus, Ohio 43205 (map)

Contact Information#

Contact Information